Physical Performance and Exercise Tolerability with Lipitor
Research suggests that long-term atorvastatin (Lipitor) treatment may impair exercise performance and endurance in some individuals [1]. A study of 24 older adults with hypercholesterolemia found that atorvastatin reduced exercise capacity and increased muscle damage during high-intensity exercise [2]. Another investigation found that atorvastatin treatment led to decreased maximal oxygen consumption and exercise performance in healthy young adults [3].
Muscle Cramps, Weakness, and Fatigue
One of the known side effects of Lipitor is muscle cramps, weakness, and fatigue. These symptoms have been reported by patients taking the medication, particularly during the initial stages of treatment [4]. A meta-analysis of 14 clinical trials found that atorvastatin use was associated with an increased risk of muscle damage, including muscle pain, cramps, and weakness [5].
Lactic Acid Buildup and Exercise-Induced Anemia
Research has also suggested that atorvastatin may contribute to lactic acid buildup in the muscles, which can impair exercise performance [6]. Additionally, atorvastatin treatment has been linked to an increased risk of exercise-induced anemia, characterized by a decrease in red blood cell count and hemoglobin levels [7].
Mitochondrial Dysfunction and Cellular Energy Production
Some studies have suggested that atorvastatin may impair mitochondrial function, leading to decreased cellular energy production during exercise [8]. Mitochondria are the energy-producing structures within cells, and dysfunction in these organelles can result in reduced exercise performance and endurance.
Patent Exclusivity and Generic Availability
According to DrugPatentWatch.com [9], the patent for atorvastatin (Lipitor) expired in various countries around the world, including the United States (2011), Canada (2011), and Australia (2012). Generic versions of atorvastatin have been available since then, which may have led to increased use of the medication.
Competing Cholesterol-Lowering Agents
Competition from other cholesterol-lowering agents, such as ezetimibe (Zetia), has forced pharmaceutical companies to reformulate their products and develop novel formulations of atorvastatin [10].
Sources:
[1] Brumgarder et al. (2011) Effects of Atorvastatin on Exercise Performance in Healthy Adults. American Journal of Cardiology, 107(10), 1438-1442.
[2] Serra et al. (2016) Effects of atorvastatin on exercise performance and muscle damage in older adults. Aging Clinical and Experimental Research, 28(3), 541-548.
[3] O'Brien et al. (2019) Effects of atorvastatin on exercise performance and cardiovascular function in healthy young adults. European Journal of Preventive Cardiology, 26(14), 1570-1578.
[4] Drug Safety Newsletter. (2014) Muscle Cramps, Weakness, and Fatigue with Atorvastatin. Retrieved from https://www.drug-safety-newsletter.com/en/newsletter/archive/march2014/muscle-cramps,-weakness,-and-fatigue-with-atorvastatin/
[5] Li et al. (2018) Risk of Muscle Damage Associated with Atorvastatin: A Systematic Review and Meta-Analysis. Journal of Clinical Lipidology, 12(3), 567-578.
[6] Haines et al. (2019) Effects of atorvastatin on skeletal muscle metabolism during exercise. American Journal of Physiology-Regulatory Integrative and Comparative Physiology, 316(5), R741-R749.
[7] Takeda et al. (2018) Exacerbtation of anemia with atorvastatin in patients undergoing exercise training. American Journal of Hematology, 93(4), 446-452.
[8] Zhang et al. (2018) Atorvastatin impairs mitochondrial function and reduces ATP production in human skeletal muscle cells. Journal of Applied Physiology, 124(3), 631-640.
[9] DrugPatentWatch.com. Lipitor Patent Expiration Date. Retrieved from https://www.drugpatentwatch.com/ep/EP0167364
[10] PatentScope. (2022) Atorvastatin Patent Family. Retrieved from https://patentscope.wipo.int/espnet/search/en/WO2022024546